Aspire Allergy & Sinus

Aspire Allergy & Sinus offers specialized allergy and sinus treatments, focusing on personalized care to help patients manage their symptoms effectively. Their innovative solutions include allergy drops and minimally invasive sinus procedures. Aspire Allergy & Sinus, founded in 2012 and headquartered in Austin, US, provides tailored allergy and sinus treatments. The company was established to address the growing need for personalized healthcare in allergy management.

CEO Allie Thompson leads the firm, which has secured funding through investments from Source Capital and Harvey & Company in July 2018, though financial terms were not disclosed. The company has concluded one significant deal since its inception. Aspire Allergy & Sinus specializes in personalized allergy and sinus treatment solutions, including allergy drops that build tolerance to specific allergens and minimally invasive sinus procedures for long-term relief. Their services cater to individuals suffering from chronic allergies and sinus infections, providing treatment options that can be administered conveniently, often requiring only a few visits.

The company serves a diverse clientele across the US, focusing on improving patients' quality of life through tailored care. In the most recent year, Aspire Allergy & Sinus reported revenue of USD 32. 80 mn, generated through direct-to-consumer transactions for its allergy and sinus treatment services. This revenue encompasses initial consultation fees and costs associated with personalized treatment plans, establishing a strong foundation for ongoing patient relationships.

Aspire Allergy & Sinus aims to leverage its recent funding to enhance its service offerings and expand into new markets. The company is exploring the development of additional treatment products tailored to specific patient needs. Furthermore, there are plans to expand geographically by targeting new urban and suburban areas across the United States by 2022, aiming to increase its reach and accessibility to patients. The recent investment will support these initiatives, positioning the company for continued growth and innovation.